As on March 31, 2024, Jubilant Pharmova has gross debt at Rs. 3,414 crore and net debt at Rs. 2,457 crore on a consolidated basis.
Jubilant Pharmova has reported Rs. 6,772 revenue and net profit Rs 195 crore in FY24. The net debt to Ebitda reduced from 2.93x as on March 31, 2023 to 2.48x as on March 31, 2024.
Jubilant Pharmova incurred elevated debt due to high capex on sterile injectables, R&D on speciality pharmaceuticals, generics and CDMO business.
Jubilant Pharmova early this year sold its entire stake in associate entity Sofie Biosciences for $139.43 million. The company said it will use the sale proceeds to deleverage balance sheet.
Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses.
